This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's NDA for SMA Drug Risdiplam Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 2.20% and 5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -43.48% and 4.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
by Zacks Equity Research
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -22.97% and -24.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: PTC Therapeutics (PTCT) Q4 Earnings Expected to Decline
by Zacks Equity Research
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
by Zacks Equity Research
Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
New Strong Sell Stocks for November 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -135.00% and -21.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About PTC Therapeutics (PTCT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PTC Therapeutics (PTCT) stock based on the movements in the options market lately.
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75.00% and -1.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
PTC Therapeutics (PTCT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in PTC Therapeutics (PTCT) Stock
by Zacks Equity Research
PTC Therapeutics (PTCT) needs investors to pay close attention to the stock based on moves in the options market lately.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
by Indrajit Bandyopadhyay
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%
by Zacks Equity Research
PTC Therapeutics (PTCT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Sarepta's Stock Soars on Encouraging Gene Therapy Results
by Zacks Equity Research
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
PTC Therapeutics' Spinal Muscular Atrophy Study Successful
by Zacks Equity Research
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options
by Zacks Equity Research
PTC Therapeutics (PTCT) needs investors to pay close attention to the stock based on moves in the options market lately.
3 Reasons Momentum Stock Investors Will Love PTC Therapeutics (PTCT)
by Zacks Equity Research
PTC Therapeutics (PTCT) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.